A Study on How NNC0174-1213 Works in People With Overweight or Obesity
Phase 1
177
about 1.5 years
18–55
Male only
2 sites in TX, UT
About this study
Researchers are testing a new medicine called NNC0174-1213 to treat people with overweight or obesity. The aim of it is to see if the medicine is safe, how it works in human body, and what human body does to it medicine. Participants will either get the new medicine NNC0174-1213, a trial medicine called cagrilintide or a placebo (a dummy medicine similar to the new trial medicine and trial medicine but without active ingredients). Which treatment participants will get is decided by chance. The new trial medicine and it medicine are potential new medicines which cannot be prescribed by doctors. It will last for about a year in total.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cagrilintide B
- 2.Take NNC0174-1213 A
- 3.Take Placebo A (NNC0174 1213 A)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213, Part B: Number of treatment emergent adverse events (TEAE)
Secondary: Part A: AUC; area under the NNC0174 1213 plasma concentration-time curve, Part A: Cmax; maximum observed NNC0174 1213 plasma concentration, Part B: AUC; area under the NNC0174 1213 plasma concentration-time curve, Part B: Cmax; maximum observed NNC0174 1213 plasma concentration
Endocrinology